Cargando…

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

Significant advances in the treatment of melanoma have been made with BRAF-targeted therapy and immune checkpoint blockade, and these strategies are now being combined empirically in clinical trials. Potential synergy is demonstrated in murine models and in analysis of longitudinal biopsies from pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Zachary A, Reuben, Alexandre, Amaria, Rodabe N, Wargo, Jennifer A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292518/ https://www.ncbi.nlm.nih.gov/pubmed/25941608 http://dx.doi.org/10.4161/21624011.2014.954956

Ejemplares similares

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade
por: Duraiswamy, Jaikumar, et al.
Publicado: (2013)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

A(2A) blockade enhances anti-metastatic immune responses
por: Beavis, Paul A, et al.
Publicado: (2013)

BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression
por: Ho, Ping-Chih, et al.
Publicado: (2014)

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014)

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
por: Kakavand, Hojabr, et al.
Publicado: (2013)

Fateful music from a talented orchestra with a wicked conductor: Connection between oncogenic BRAF, ER stress, and autophagy in human melanoma
por: Giglio, Paola, et al.
Publicado: (2015)

Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
por: Espinosa, Lluís
Publicado: (2015)

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
por: Herr, Ricarda, et al.
Publicado: (2015)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
por: Cooper, Zachary A., et al.
Publicado: (2016)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Melanoma metastases caught in the AKT
por: Kircher, David A., et al.
Publicado: (2016)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
por: Zhang, Mengxian, et al.
Publicado: (2012)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Sloane, Robert A. Szczepaniak, et al.
Publicado: (2021)

A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

CDK1/2/5 blockade: killing two birds with one stone
por: Liu, Jiao, et al.
Publicado: (2021)

Sustaining the spindle assembly checkpoint to improve cancer therapy
por: Visconti, Roberta, et al.
Publicado: (2015)

The mitosis-differentiation checkpoint, another guardian of the epidermal genome
por: Gandarillas, Alberto, et al.
Publicado: (2015)

Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition
por: McQuade, Jennifer L, et al.
Publicado: (2015)

Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators
por: Hatfield, Stephen M, et al.
Publicado: (2015)

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
por: Peng, Weiyi, et al.
Publicado: (2013)

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity
por: Kortylewski, Marcin, et al.
Publicado: (2014)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
por: Codarri Deak, Laura, et al.
Publicado: (2023)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2hglb0fs2p6hadpgsbk2u9cf34